<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83384">
  <stage>Registered</stage>
  <submitdate>22/11/2008</submitdate>
  <approvaldate>8/05/2009</approvaldate>
  <actrnumber>ACTRN12609000232235</actrnumber>
  <trial_identification>
    <studytitle>Study to Investigate the Effects of Coenzyme Q10 Supplementation on Cardiovascular Health in Males Receiving Statin Medication for High Cholesterol Levels</studytitle>
    <scientifictitle>Randomised, double blind, placebo controlled, cross over study to investigate the effect of dietary supplementation with coenzyme Q10 on endothelial function in males with the metabolic syndrome who are concurrently on statin treatment.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Dyslipidemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Coenzyme Q10 dietary supplement is a tablet (100mg) to be taken orally, twice daily for 3 months. There is a 1 month washout period between intervention and control or vice versa depending on treatment allocation.</interventions>
    <comparator>Placebo is a sugar pill to be taken orally as 2 tablets twice daily for 3 months.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Flow-mediated dilation of the brachial artery (endothelium dependent function) to be assessed with ultrasound.</outcome>
      <timepoint>At baseline and at 3 months after intervention commencement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Endothelial independent dilation of the brachial artery to be assessed with ultrasound.</outcome>
      <timepoint>At baseline and at 3 months after intervention commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Augmentation index using a medical device with a pressure sensor to measure the siffness of the blood vessels.</outcome>
      <timepoint>At baseline and at 3 months after intervention commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Systolic and diastolic blood pressure assessed with an automated blood pressure monitor.</outcome>
      <timepoint>At baseline and at 3 months after intervention commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Markers of cardiovascular risk measured from blood tests.</outcome>
      <timepoint>At baseline and at 3 months after intervention commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Coenzyme Q10 levels measured from a blood test.</outcome>
      <timepoint>At baseline and at 3 months after intervention commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life Scores assessed using a Quality of Life Questionnaire.</outcome>
      <timepoint>At baseline and at 3 months after intervention commencement</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Waist circumference &gt;= 94cm
Triglycerides &gt;=1.7 mmol/L or specific therapy for tirglycerides
Systolic blood presure &gt;=130 mmHg or Diastolic blood pressure &gt;=85 mmHg or treatment for hypertension
Statin naive or treatment with &lt;=40mg/day simvastatin or equivalent</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pre-treatment Low-density Lipoprotein (LDL)-cholesterol &lt;1.5mmol/L or &gt;6.5 mmol/L
Pre-treatment triglycerides &gt;5 mmol/L
History of cardiovascular event or intervention within the 6 months prior to screening
Type 1 diabetes mellitus
Type 2 diabetes mellitus requiring oral anti-diabetic agents or insulin
Current smoker
Treatment with fibrates or other lipid modifying agents other than statin therapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered containers</concealment>
    <sequence>Permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/10/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Lipid and Diabetes Research Group</primarysponsorname>
    <primarysponsoraddress>First Floor, Hagley Hostel
Christchurch Hospital
Private Bag 4710
Christchurch 8140</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Heart Foundation of New Zealand (NZ)</fundingname>
      <fundingaddress>PO Box 17160
Greenlane
Auckland 1546</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Clinical Biochemistry Unit</sponsorname>
      <sponsoraddress>Canterbury Health Laboratories
Corner Hagley Ave and Tuam Street
P O Box 151
Christchurch 8140</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Coenzyme Q10 supplementation is increasingly used for the prevention of heart disease. Supplementation with coenzyme Q10 has been shown to improve cardiovascular function in people with type 2 diabetes. Improving cardiovascular function can reduce the risk of heart disease.  In a previous study we found that reductions in coenzyme Q10 levels due to statin therapy were associated with improvements in cardiovascular function. We hypothesised that coenzyme Q10 supplementation may enhance the beneficial effect of statin treatment and further contribute to reducing the risk of heart disease. The study aims to investigate whether supplementation with coenzyme Q10 can further improve cardiovascular function in patients taking statin medication and thereby give additional benefit to statin treatment in protection from heart disease.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Upper South B Regional Ethics Committee</ethicname>
      <ethicaddress>Upper South B Ethics Committee
Ministry of Health
4th Floor, 250 Oxford Tce
PO Box 3877
Christchurch 8140</ethicaddress>
      <ethicapprovaldate />
      <hrec>URB/05/06/077</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jo Young</name>
      <address>Lipid and Diabetes Research Group
First Floor, Hagley Hostel
Christchurch Hospital
Private Bag 4710
Christchurch 8140</address>
      <phone>+64 3 364 1186</phone>
      <fax>+64 3 364 0457</fax>
      <email>joanna.young@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jo Young</name>
      <address>Lipid and Diabetes Research Group
First Floor, Hagley Hostel
Christchurch Hospital
Private Bag 4710
Christchurch 8140</address>
      <phone>+64 3 364 1186</phone>
      <fax>+64 3 364 0457</fax>
      <email>joanna.young@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jo Young</name>
      <address>Lipid and Diabetes Research Group
First Floor, Hagley Hostel
Christchurch Hospital
Private Bag 4710
Christchurch 8140</address>
      <phone>+64 3 364 1186</phone>
      <fax>+64 3 364 0457</fax>
      <email>joanna.young@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>